Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma is a PHASE1 clinical asset sponsored by University College, London in Primary CNS Lymphoma. SEO and diligence focus: CD19CAR T-cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Primary CNS Lymphoma
Modality: protein therapy
Target: CD19CAR T-cells
Sponsor: University College, London
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19CAR T-cells
View original source fields
Condition raw: Primary CNS Lymphoma
Condition normalized: Primary CNS Lymphoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19CAR T-cells
Target normalized: CD19CAR T-cells